Standard BioTools Raises FY23 Revenue Outlook From $80M-$84M To $100M-$105M
Portfolio Pulse from Benzinga Newsdesk
Standard BioTools has raised its FY23 revenue outlook from $80M-$84M to $100M-$105M. SomaLogic reaffirmed its full year 2023 revenue guidance of $80 - $84 million.
October 04, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Standard BioTools, potentially associated with the symbol LAB, has raised its FY23 revenue outlook, which could positively impact its stock price.
Companies often see their stock prices increase when they raise their revenue outlooks, as this suggests they expect to perform better financially in the future. This is the case for Standard BioTools, which has raised its FY23 revenue outlook from $80M-$84M to $100M-$105M.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100